Try our beta test site
9 studies found for:    Open Studies | Hodgkin's | Phase 3
Show Display Options
Rank Status Study
1 Recruiting HD17 for Intermediate Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);   Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine);   Radiation: 30Gy IF-RT (Involved-Field Radiotherapy);   Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)
2 Recruiting Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Condition: Hodgkin Lymphoma
Interventions: Biological: pembrolizumab;   Biological: brentuximab vedotin
3 Recruiting Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Condition: Classical Hodgkin Lymphoma
Interventions: Drug: cyclophosphamide, vincristine, prednisone, dacarbazine;   Drug: cyclo, vcr, pred, dacarb,etop and doxo
4 Recruiting Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim);   Drug: Cytosine arabinoside with G-CSF (filgrastim)
5 Not yet recruiting HD21 for Advanced Stages
Condition: Classical Hodgkin Lymphoma
Interventions: Drug: Bleomycin;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Procarbazine;   Drug: Prednisone;   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Dexamethasone
6 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
7 Recruiting Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
Interventions: Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
8 Recruiting Double Cord Versus Haploidentical (BMT CTN 1101)
Conditions: Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Biological: Haploidentical Bone Marrow Transplant;   Biological: Double Umbilical Cord Blood Transplant
9 Recruiting Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
Interventions: Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)

Study has passed its completion date and status has not been verified in more than two years.